IL317580A - תאי קולט אנטיגנים כימריים משופרים תלויי גליקן - Google Patents

תאי קולט אנטיגנים כימריים משופרים תלויי גליקן

Info

Publication number
IL317580A
IL317580A IL317580A IL31758024A IL317580A IL 317580 A IL317580 A IL 317580A IL 317580 A IL317580 A IL 317580A IL 31758024 A IL31758024 A IL 31758024A IL 317580 A IL317580 A IL 317580A
Authority
IL
Israel
Prior art keywords
cell
car
antigen
modified cell
domain
Prior art date
Application number
IL317580A
Other languages
English (en)
Inventor
Michael Demetriou
Raymond Wenhou Zhou
Yanni Zhu
Original Assignee
Univ California
Michael Demetriou
Raymond Wenhou Zhou
Yanni Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Michael Demetriou, Raymond Wenhou Zhou, Yanni Zhu filed Critical Univ California
Publication of IL317580A publication Critical patent/IL317580A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL317580A 2022-06-13 2023-06-09 תאי קולט אנטיגנים כימריים משופרים תלויי גליקן IL317580A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263351746P 2022-06-13 2022-06-13
PCT/US2023/024956 WO2023244511A2 (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells

Publications (1)

Publication Number Publication Date
IL317580A true IL317580A (he) 2025-02-01

Family

ID=89191814

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317580A IL317580A (he) 2022-06-13 2023-06-09 תאי קולט אנטיגנים כימריים משופרים תלויי גליקן

Country Status (9)

Country Link
EP (1) EP4536282A2 (he)
JP (1) JP2025520384A (he)
KR (1) KR20250036972A (he)
CN (1) CN119698297A (he)
AU (1) AU2023292081A1 (he)
CA (1) CA3258445A1 (he)
IL (1) IL317580A (he)
MX (1) MX2024015583A (he)
WO (1) WO2023244511A2 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111484A1 (en) * 2023-11-21 2025-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cellular therapies targeting aberrant glycosylation in solid malignancies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016257721B2 (en) * 2015-05-01 2019-11-14 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
CN110121505B (zh) * 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
AU2018243571B2 (en) * 2017-03-31 2024-03-07 The Board Of Trustees Of The Leland Standford Junior University Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling

Also Published As

Publication number Publication date
KR20250036972A (ko) 2025-03-14
AU2023292081A1 (en) 2025-01-09
CN119698297A (zh) 2025-03-25
MX2024015583A (es) 2025-04-02
WO2023244511A3 (en) 2024-02-29
WO2023244511A2 (en) 2023-12-21
EP4536282A2 (en) 2025-04-16
JP2025520384A (ja) 2025-07-03
CA3258445A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
US11666660B2 (en) Glycan-dependent immunotherapeutic molecules
US20250361318A1 (en) Improved glycan-dependent immunotherapeutic bi-specific proteins with longer half-life
EP4536282A2 (en) Improved glycan-dependent chimeric antigen receptor cells
WO2023244499A2 (en) Improved glycan-dependent immunotherapeutic bi-specific fusion proteins and chimeric antigen receptors
HK40120452A (zh) 改进的聚糖依赖性嵌合抗原受体细胞
HK40119970A (zh) 改进的聚糖依赖性免疫治疗性双特异性融合蛋白和嵌合抗原受体
HK40122502A (zh) 具有更长半衰期的改进的聚糖依赖性免疫治疗性双特异性蛋白
HK40083189A (en) Glycan-dependent immunotherapeutic molecules